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IT is the aim of the present article to contribute to the study of conditions
for transplantation of human malignant tumours to mice.
Already from studies by Loeb (1901) and C. O. Jensen (1902, 1903) it appeared
that heredity and immunity would play an important part in the fate of tumour
grafts, and this view was further elaborated by Murphy (1913), Tyzzer (1916a,
1916b) and Bittner (1931). According to these authors, the more foreign the cells
the more powerful they are as antigens, and the so-called " secondary immunity"
would therefore be expected to be pronounced when human tumour cells are
transferred to animals. Consequently, it seemed necessary to avoid or at least to
reduce the immunitory response in experimental animals, if attempts at hetero-
logous transplantation should have any chance of success.
Some workers have chosen to transplant into newborn animals (Gheorghiu,
1926) with only feeble immunitory response, others to the anterior chamber of
the eye (Keysser, 1913; Smirnova, 1937; Greene, 1938, 1941, 1947, 1948, 1950;
Greene and Lund, 1944; Towbin, 1951a), and others to the brain (Greene, 1951;
Albrink and Greene, 1953) in which organs no such response seems to be released.
In order to facilitate heterologous transplantation, universal roentgen irradi-
ation was introduced by Murphy (1914), and later elaborated by Krebs and
associates (Wagner, 1930; Krebs and Busch, 1931; Clemmesen, 1940; Bichel
and Holm-Jensen, 1949) using heavy doses before subcutaneous or intramuscular
transplantations as a means ofeliminating the formation ofantibodies. However,
roentgen irradiation is inefficient in having only temporary effect, and is particu-
larly unsuited for the transmission of human tumours (Toolan, 1951), which
will be followed by a relatively long latent period before an eventual take (Towbin,
1951b). Furthermore, a second irradiation might interfere with the life of the
transplanted cells.
On the contrary, cortisone in heavy daily doses will restrain the function of
antibody-producing centres without significant damage to the graft. Only tumours
oflymphoid origin will, like normal lymphoid tissue, be considerably hampered by
heavy doses of the hormone (Pearson, Eliel and Rawson, 1950; Spies, Stone,
Lopez, Milanes, Toca and Reboredo, 1950; Kirschbaum, 1951; Block and
Jacobson, 1952).
Thus, Green and Whiteley (1952) found that massive doses of cortisone would
considerably prolong the survival ofhuman tumours transplanted to experimental
animals, and these observations were confirmed by Toolan (1953), who later (1954)
succeeded in keeping three human squamous cell carcinomas and two human
sarcomas alive through alternate passages in rats treated with cortisone and in
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the cheek pouch of hamsters. Patterson, Chute and Sommers (1954) similarly
succeeded in transmitting a human squamous cell carcinoma through many
passages in the cheek pouch of hamsters treated with cortisone. It appeared
from these publications that a few out of a series of tumours tested showed
capacity of growth in the heterologous host, but only when the production of
antibodies was suppressed with cortisone.
Author's Experiments.-In the experiments reported in the following the
author has exploited the possibilities for heterologous transplantation studies
offered at the Finsen Institute and Radium Centre in Copenhagen. Here a large
number ofpatients with malignant diseases are concentrated close to experimental
laboratories.
MATERIAL AND METHODS
Experimental animals were mice belonging to a subline of the so-called Bagg
strain, which shows a low incidence of spontaneous tumours, according to Engel-
breth-Holm (1956, personal communication) 5 per cent out of 343 animals.
Only one mouse under ten months of age developed a spontaneous tumour
(leucemia). At transplantation, animals weighed 17 to 20 grams, and were 2 to
3 months old. Equal numbers of each sex were entered into experimental and
control groups.
Cortisone treatment began at least four days before transplantation, and
continued with a daily dose of 1 mg. until the animal died or was killed. In order
to keep the dosage of cortisone precise, the employed solution of hormone,
"Cortone Merck ", was diluted up to a concentration of 1 mg. cortisone in 0.1
ml. of the solution. Control animals had daily injections of 0-1 ml. physiological
NaCl. In order to obtain an universal effect, the hormone was injected intra-
peritoneally at subcutaneous or intra-ocular transplantations, and subcutaneously
at intraperitoneal inoculations.
In afewexceptionalseriesitwas attemptedtoincrease theeffect ofthehormone
by universal roentgen irradiation 24 hours before transplantations (dosage:
200 r; intensity: 26.4r/min.; HVL: 1.0 mm. Cu; 180 kilovolt; 6 milliamp.;
0.5 mm. Cu-filter).
Tumours were minced with scissors and injected into animals by means of
a syringe with a screw-driven piston. At subcutaneous and intraperitoneal
inoculations the transplant amounted to 0.05 ml. of the mince, while ascites
fluid was injected in quantities of 0.5 ml. on account of the relatively smaller
contents of tumour cells. The intra-ocular transplantations were carried out on
ether anaesthetized animals. Through a cut at the upper cornea-scleral junction
a butt canula was introduced, containing tumour mince, which could be pushed
out by means of a well-fitting mandrin. On account of the small dimensions of
the mouse eye, the application ofthe graft was not always quite successful.
All transplantations were undertaken alternately to cortisone-treated and
control animals. Instruments were sterilized in boiling water for 20 minutes.
As a rule, human tumours used were metastases or local recurrences, which
were supposed to have the greatest possibilities of taking. Transplantation
material was removed from patients during operation under general anaesthesia,
and immediately brought to the laboratory. Usually 15 or 20, but in no case more
than 30 minutes elapsed from the cessation ofblood supplyto the tissue in question
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until all animals had been transplanted. Inoculation of ascites fluid was always
finished within 5 min. after puncture.
In the transplantation series where tumour mince was used, animals were
killed at fixed intervals, usually with one mouse from each group, starting at the
tenth day after transplantation and subsequently every fifth day. Mice inoculated
with ascites fluid were not killed, but examined by punctures, usually every
tenth day.
RESULTS
Transplantation results with 21 different human tumours are shown in Tables I
and II. It appears that in the cortisone-treated groups of 12 experimental series,
tumour tissue apparently capable of living was found at the site of inoculation
after the tenth day in at least one animal, while the grafts in control mice had
completely disappeared, leaving a dense infiltration of lymphocytes and granu-
locytes. Such foreign-body reaction was never found in animals treated with
cortisone..
In the series where tumour mince had been used for transplantation, tumour
tissue was demonstrated up to 45 days later, but without proliferation or invasive-
ness, though it appeared capable ofliving and had kept its characteristics (Fig. 1
and 2).
No difference between the results of subcutaneous and intraperitoneal appli-
cation of the graft could be distinguished, and adaptation of the tumours to
cortisone-treated animals was not furthered by roentgen irradiation or by trans-
plantation to the anterior chamber ofthe eye.
In one of the two cases in which inoculation of human ascites fluid into the
peritoneum of mice was attempted, it resulted in the formation of an ascites
tumour which has now been transmitted through 41 serial passages in mice of
Bagg's strain (March 1956). The ascites fluid in this case was particularly rich
in cells, and presented some other features worth mentioning.
The Ascites Tumour H.A.I
Case history.-In brief the case history of the patient was the following:
Female aged 75, born 1879 (R. No. 64561). Syphilis was ascertained 1930, but
never treated. Since 1934liver function had been failing as indicated by formation
ofascites andpositive results from liver functiontests. In 1939 an adenocarcinoma
developed in the right breast with metastases to axillary lymph nodes (Fig. 3).
Radical operation was attempted but presumably without full success. No
radiation treatment. Roentgenographic changes in spinal column and pelvis
weresuspiciousofmalignancy, but noproofwas attained. In 1952asolidcarcinoma
ofthe cervix (Stage III) (Fig. 4) was treated with roentgen irradiation and radium,
but cachexia developed accompanied by increasing ascites which had to be
drained every seconq week. Cytological examination of ascites smears showed
large numbers of cells differing in size, in number of nuclei and showing many
mitoses (Fig. 5), but without tissue characteristics. Death occurred in March
1955, andautopsyshowedmetastases from asquamous cell carcinomainabdominal
lymph nodes, peritoneum and peritoneal fat. The osseous changes mentioned
above were not verified at autopsy.
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TABLE II.--List of Human Tumours Transferred to Mice Treated with Cortisone,
Cortisone + Roentgen Irradiation or Roentgen Irradiation alone, but regressing
within 10 days in both Treated and Untreated Mice.
Number of mice
Patient Source of Cort. Con-
No. Sex. Tumnour. graft. Application. Cort. +Rtg. Rtg. trol
Z.1826 m. Adenocarcinoina . Lymph node Subcutaneous 10 10
(Stomach) metastasis
Z. 1900 m. . Adenocarcinoma Skin Intraperitoneal . 3 5
(Stomach) metastasis Subcutaneous. 5 5
Z.2013 . f. . do. Liver do. . 5 4 5 5
metastasis 4 5 5 5
Z.1843 m. Malignant Primary site Intraperitoneal . 9 9
melanoma
Z.1783 . f. . do. . Lymph node Intraperitoneal 5 - 5
metastasis Subcutaneous 10 -- 9
Z.1937 f. . Hodgkin's . Spleen . do. 5
disease 4 5
Z.1818 f. . Solid carcinoma Primary site Intraperitoneal 8 10
(Bladder) Intraocular 5 -- 5
R.74760 . m. . Adenocarcinoma Testis . Subcutaneous . 10 9 9 10
(Prostate) metastasis
1.78083 f. Adenocarcinoma Ascites Intraperitoneal . ]10 8 - 10
(Ovary)
Transmission to mice.-Ascites fluid recovered seven months before death,
and immediately injected into peritoneum of ten mice treated with cortisone,
and ten controls, caused no immediate response except the death of one experi-
mental animal on the day of inoculation.
Twenty-eight days later two female and one male mouse had developed marked
distention of the abdomen, which increased rapidly so that all these animals
were unmistakably distended from about the 45th day (Fig. 6). In all three
cases punctures on the 25th day resulted in yellowish, slightly turbid fluid
containing numerous tumour cells, closely similar to the patient's although
perhaps varying more in size (Fig. 7). Some of them showed profiounced
vacuolation. Cells from the mice had no admixture of granulocytes, which was
pronounced in the human ascites.
A fourth experimental female mouse developed increase in abdominal size
following the 52nd day, and gave the same results from cytological examnination
of ascites as already described.
Serial transmission of the ascites tumour H.A.1
On the 35th day ascitic fluid from each of two females out of the first three
positives was transmitted into five cortisone-treated and five control animals.
The twenty animals of this second passage each received 0.1 ml.
As shown in Table III, all of the ten cortisone-treated animals developed
ascites, observable from the 20th day, from which date it increased rapidly until
death occurred, on the average 56 days after inoculation. Repeated punctures
gave fluid with a cytological picture corresponding to the description given above.
It should be noted that there was complete identity in picture between fluids
from the two groups of animals derived from each of the two mice in the first
passage.HUMAN TUMOURS IN MICE
Ascites developed in none of the control mice from the first two passages,
and at autopsy three months after inoculation neither controls nor negative
cortisone-treated animals showed any abnormal findings.
It is worthy of particular notice that the animals from the first two passages
in which inoculation caused ascites, showed nothing abnormal at autopsy except
the ascitic fluid amounting to almost 8 grams on the average (Table III). Histo-
logical examination of the peritoneum and abdominal organs showed no
pathological change.
TABLE III.--The Ascites Tumour H.A.1. in the First Passages in Mice.
Average amount
Number of mice Average lifetime of ascites
Passage No. Treatment. with ascites. in days. in grams.
1 Cortisone . 4/9 . 66-5 (53-88) . 7.9 Controls 0/10 'Controls . 0/10 --.-
2 Cortisone 10/10 . 56-0 (46-63) . 7.7 Controls . 0/10
3 Cortisone 9/9 32-4 (25-41) . 8-6
Controls 10/10 . 36.2 (24-50) . 6.4
4 ICortisone 10/10 . 30-9 (24-38) . 7.4 Controls . 10/10 . 28.7 (19-40) 7-1
The third passage originated from ascitic fluid recovered from the previous
passage 35 days after transmission, and inoculated into ten cortisone-treated
animals and ten controls. In this third passage, however, the formation of ascites
occurred also in the untreated controls, abdominal distention being noticeable in
treated and untreated animals between the tenth and fifteenth day. Henceforth,
the abdominal increase developed considerably more rapidly than in the previous
two passages, and the lifetime of the animals was correspondingly shortened in
both groups (Table III).
A fourth transmission was carried out on both cortisone-treated and untreated
mice, but as the ascites tumour now seemed to grow equally well in the two
groups, serial transmission was continued in normal mice only.
The tumour has up to now (March 1956) been propagated through 41 passages,
each comprising ten mice, five of each sex. The inoculation dose has been kept
at 0.1 ml., and the ascitic fluid recovered at autopsy usually amounts to between
seven and ten grams.
From the third passage inoculation has not failed to cause ascites tumour in
any case, and development of the latter has taken place with increasing rapidity,
incipient distention now appearing 3 to 4 days after inoculation. In the last ten
passages the average life time after inoculation has been 18 days for males and
15 days for females.
While autopsy in the first two passages did not disclose any solid tumours
or metastases, all mice in the third and following passages have shown extensive
semi-solid and solid tumour growths (Fig. 8), often with infiltration of intestine,
stomach, pancreas, liver, kidneys and lymph nodes (Fig. 9 and 10). Distant
metastases were not observed.
DISCUSSION
The favourable effect of cortisone on inoculates of human tumour cells in mice
may be attributable to a depressing action of the hormone on the production of
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antibodies (Stoerk and Solotorovsky, 1950; Bj0rneboe, Fischel and Stoerk,
1951; Kass, Kendrick and Finland, 1953). A further effect may be due to a
decrease in the number of macrophages (Baker, 1952) together with a reduction
in their phagocytic capacity (Gordon and Katsh, 1949; Holden, Seegal and Ryby,
1951; Nicol and Snell, 1954).
When solid tumours or tumour mince is employed as transplantation material,
a proliferation ofthe malignant cells will require a supply ofstroma from the host.
Generally, this appears to be one of the worst obstacles to successful transplanta-
tion of heterologous tumours. Clemmesen in his monograph (1938) ascribes the
growth of mouse tumours obtained in his experiments on roentgen irradiated
rats largely to the use of tumours primarily poor in stroma. Furthermore, as
cortisone is known to have a restrictive influence on the formation of connective
tissue (Ragan, Howes, Plotz, Meyer and Blunt, 1949; Spain, Molomut and Haber,
1950; Cornman, 1951; Cavallero, Borasi, Sala and Amira, 1951; Taubenhaus,
1953), the possibilities of stroma formation, and thus of growth of the graft,
will be very poor in animals treated with the hormone. Correspondingly in the
author's experiments no proliferation oftumour cells was seen in solid grafts.
However, in one ofthe two experimental series on human ascites with tumour
cells needing no stroma, an ascites tumour developedinmicetreatedwithcortisone.
On serial transmission these tumour cells seemed to have adapted themselves to
such an extent that on and after the third passage no cortisone treatment was
necessary, as the procreative power ofthe cells had increased through the passages.
It was only after this time that the cells proved capable of forming solid masses
and thus of obtaining a scanty stroma support from their new host, whether
treated with cortisone or not (Fig. 8).
It appears from studies by Klein (1951) that intra-abdominal implantation
may facilitate the taking of certain tumours, and the positive result from intra-
peritoneal grafting of ascitic fluid here reported might not be accidental.
However, the morphological conformity between ascites tumour from mice
and humans may perhaps be a coincidence. But that the ascites tumour in the
mice should be spontaneous and independent of the transmitted human cells
would seem unlikely, as cells of identical type developed in 4 out of 9 cortisone-
treated mice, and the first serial transmissions required animals with lowered
capacity of antibody formation. Besides, spontaneous ascites tumours in this
mouse strain have never been observed in the present laboratory.
To the author it seems more likely that a survival in the human ascites of
cells with marked capacity ofmutation has resulted in a selection of cells particu-
larly suited for this kind oftransmission, but the chromosome types in the ascites
tumour is now under further analysis.
SUMMARY
Attempts at transplantation of 21 different human neoplasms to cortisone-
treated mice are recorded. After injection of tumours minced with scissors,
tumour tissue survived for 10-45 days in treated animals in 11 out of 19 series.
Though apparently capable of living, the malignant cells did not show prolifera-
tion or invasiveness, probably chiefly because of difficulties in obtaining stroma
from the new host.
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In one of two series where human ascites, containing tumour cells, was used
as transplantation material, an ascites tumour formed in 4 out of 9 cortisone-
treated mice. This tumour, till now (March 1956) carried in 41 passages, has
shown increasing growth rate, and from the third passage it was able to grow also
in untreated animals, and to form infiltrating solid tumour masses in the latter.
Thus, human tumour cells seem to have been established in normal experimental
animals.
I am indebted to Senior Surgeon A. Zacho and Professor J. Nielsen for interest
and helpful advice, and to Senior Pathologist J. Clemmesen for encouragement
and instruction.
This study was helped by a grant from the Fund of P. Carl Petersen.
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EXPLANATION OF PLATES
FiG. 1.-Metastatic skin tumour from human adenocarcinoma of oesophagus (Patient No.
Z.1519). Haematoxylin-eosin. x 250.
FIG. 2.-Transplantation site in a mouse 45 days after subcutaneous grafting of human
oesophageal adenocarcinoma shown in Fig. 1. Note preservation of structure. Haemat-
oxylin-eosin. x 250.
FIG. 3.-Breast cancer of the patient No. R.64561. Adenocarcinoma with marked mucoid
degeneration. Haematoxylin-eosin. x 65.
FIG. 4.-Solid carcinoma of cervix from patient No. R.64561. Haematoxylin-eosin. x 250.
FIG. 5.-Ascites smear from patient No. R.64561. Large number of tumour cells varying
in size and shape. Pronounced admixture of granulocytes. Haematoxylin-eosin.
x 365.
FIG. 6.-Three cortisone-treated mice and one control (left) 45 days after intra-abdominal
inoculation of human ascites (from patient No. R.64561). Marked abdominal distention
in all the treated mice.
FIG. 7.-Ascites smear from a cortisone-treated mouse 35 days after inoculation of the
patient's ascites fluid. Tumour cells varying in size, shape and in number of nuclei. Pro-
nounced vacuolation of the cytoplasm. Haematoxylin-eosin. x 425.
FIG. 8.-Solid tumour growth in a cortisone-treated mouse from the third passage of the
ascites tumour H.A.1. Note existence of capillaries and the scarcity of stroma. Haema-
toxylin-eosin. x 300.
FIG. 9.-Tumour infiltration of kidney in an untreated mouse from the third passage of the
ascites tumour H.A.1. Haematoxylin-eosin. x 300.
FIG. 10.-Tumour infiltration of pancreas in an untreated mouse from the fourth passage
of the ascites tumour H.A.1. Haematoxylin-eosin. x 300.BRITISH JOURNAL OF CANCER.
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